The emergency holds—just as a vaccine study gets underway. So what, exactly, are we meant to feel optimistic about? If you're just joining us: the DRC Bundibugyo outbreak was officially declared in May, though reporting raised concern it may have been circulating earlier. Before this review, MSF warned it was spreading geographically: South Ubangi became the seventh affected province, while North Kivu accounted for nearly half of newly confirmed cases. This is Ebola Watch. A vaccine study is underway, Uganda is getting new preparedness funding, and the emergency designation isn't budging. Let's start with the optimism—and the warning attached to it. From ReliefWeb:
After reviewing the latest epidemiological, operational and scientific evidence, the ECG supports a position of cautious optimism. Declines in cases and deaths in some hotspots, including Ituri, are encouraging, but the situation remains heterogeneous, with increases in some health zones, particularly in North Kivu. The available data do not yet confirm that the outbreak has reached its peak.
On the DRC Bundibugyo outbreak, Africa CDC's review says the emergency status should stay in place. Ituri's decline is encouraging, but North Kivu is rising, and the group says plainly that the data do not confirm a peak. “Cautious optimism” and “we can’t say it’s peaked” are two very different signals in one communiqué. If you've got family traveling through the region, hear the second one clearly: this remains Africa CDC's highest continental alert. The concern is operational: persistent community deaths, missed contacts, and disrupted basic health services. Four months after the May designation, control is still uneven from one health zone to the next. So progress in Ituri counts—but it doesn't cancel out North Kivu. The map is improving in places and worsening in others, which is why Africa CDC kept the emergency designation. The Eastleigh Voice, with Bashir Mbuthia:
The BRAVO study, launched on Saturday in Bunia, Ituri Province, will track 20,000 health and other frontline workers in Ituri and North Kivu, two provinces where responders face a high risk of exposure while working to contain the outbreak. It will examine the effectiveness of the ERVEBO vaccine against the Bundibugyo virus, which is driving the current outbreak.
MSF and Epicentre are enrolling 20,000 frontline workers in Ituri and North Kivu. That's serious scale—but it's happening while North Kivu is still one of the places getting worse. And BRAVO is testing ERVEBO against Bundibugyo, the virus driving this outbreak. ERVEBO is licensed for Zaire ebolavirus; protection here hasn't been established. That's why this study matters. The article says 70,000 ERVEBO doses were allocated from the global stockpile for this Phase 3 trial. Twenty thousand workers is a substantial cohort. I'd still want a clear answer on how those study allocations fit alongside doses for wider outbreak control. BRAVO can answer a question a compassionate-use rollout can't: among people with repeated exposure, does vaccination actually reduce Bundibugyo disease? The evidence will matter well beyond Bunia, but it won't tell us whether the outbreak has peaked. If vaccination starts with health workers in Bunia while cases are reaching new areas, can it protect the wider community—or is it mainly protecting the response teams? What would need to follow for it to make a measurable difference? Here's the key limitation: the World Health Organization says lab testing confirmed Bundibugyo virus disease, a species of Ebola, in eight of 13 samples analyzed in May. Reporting on the Bunia rollout says ERVEBO was developed for a different Ebola strain, while the Bundibugyo virus driving this outbreak has no licensed vaccine. Officials and the public shouldn't treat it as a proven, strain-matched shield for everyone in the affected areas. The rollout starts with health workers, whom the provincial governor described as particularly exposed and deeply involved in the response. Al Jazeera reports that 50,000 frontline staff are to receive the shot, with 20,000 enrolled in a one-year clinical trial. Any community benefit is indirect: keeping response workers safer and available could help sustain care and outbreak-control work, but the reporting does not establish that ERVEBO prevents Bundibugyo virus disease. It's a targeted protection-and-research effort, and the rest of the response still matters. So if the vaccine's benefit against this strain is still uncertain, what turns this from a limited workforce measure into something that can actually slow transmission? That means a community-centred response alongside the vaccination effort. CDC describes frontline infection-prevention training and community education as core tools for containing Ebola at its source, and a WHO official told UN News that outbreaks begin and end in communities. Watch for whether authorities pair the worker rollout with those measures—and whether the clinical trial produces evidence of protection against the virus identified in this outbreak. Here's Catherine Namugerwa at Nilepost:
Action Against Hunger has received about Shs3.5 billion from the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) to strengthen Ebola preparedness and prevention efforts in Uganda as an Ebola Bundibugyo virus (EBV) outbreak in neighbouring Democratic Republic of Congo continues to spread closer to the Ugandan border.
Uganda has Shs3.5 billion from OCHA moving into border preparedness—surveillance, screening, training, and infection control. For families near the DRC border, that's a concrete sign officials see a cross-border risk worth funding now. And it's routed through Action Against Hunger, focused on high-risk entry points and health-worker training. With Kinshasa and Kampala under diplomatic strain, the route that money takes matters; preparedness still has to reach the people doing the screening. But Shs3.5 billion buys readiness, not a sealed border. If North Kivu is intensifying, screening only works when people recognize symptoms, report early, and trust the health team on the other side of the checkpoint. Exactly. No cross-border transmission has been established. Uganda is preparing because the Africa CDC emergency designation shows the outbreak remains heterogeneous and unresolved. If Ebola Watch helps you stay informed, please subscribe and leave us a review wherever you're listening. Reviews help other people find the show.
We'll be watching BRAVO's first three months of vaccination, followed by at least six months of participant follow-up. Links to every story are in the show notes, so check out the pieces that caught your attention. That's Ebola Watch for today. This is a Lantern Podcast.